Floatz logo

FLUTICASONE

Leukemia

Virginia Commonwealth UniversitySmall moleculePhase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
68/ 100
Competitive Position
65/ 100

Competitive context

123 Active assets in the Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
Idarubicine
Affiliated Hospital of Nantong University
Phase 3BB
THIOGUANINE ANHYDROUS
Incyte Corporation
Phase 3BB
MERCAPTOPURINE ANHYDROUS
Dana-Farber Cancer Institute
Phase 3BB
Daunorubicin
Richard Stone, MD
Phase 3BB

View all 50 →

Same molecule, other indications

FLUTICASONE is also rated in:

Unspecified Adult Solid Tumor, Protocol SpecificDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Adult Acute Myeloid LeukemiaDormant
BBB
Indicative ·
73 / 100
View asset →
Chronic Phase Chronic Myelogenous LeukemiaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →